Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity
Regina S. Salvat,Deeptak Verma,Andrew S. Parker,Jack R Kirsch,Seth A. Brooks,Chris Bailey-Kellogg,Karl E. Griswold +6 more
TL;DR: It is demonstrated that a multiobjective library-design method enables incorporation of mutations throughout the protein, modifying portions that trigger immune recognition while simultaneously preserving stability and catalytic activity, and could enable functional deimmunization of other biotherapeutic agents.
read more
Abstract: Therapeutic proteins of wide-ranging function hold great promise for treating disease, but immune surveillance of these macromolecules can drive an antidrug immune response that compromises efficacy and even undermines safety. To eliminate widespread T-cell epitopes in any biotherapeutic and thereby mitigate this key source of detrimental immune recognition, we developed a Pareto optimal deimmunization library design algorithm that optimizes protein libraries to account for the simultaneous effects of combinations of mutations on both molecular function and epitope content. Active variants identified by high-throughput screening are thus inherently likely to be deimmunized. Functional screening of an optimized 10-site library (1,536 variants) of P99 β-lactamase (P99βL), a component of ADEPT cancer therapies, revealed that the population possessed high overall fitness, and comprehensive analysis of peptide-MHC II immunoreactivity showed the population possessed lower average immunogenic potential than the wild-type enzyme. Although similar functional screening of an optimized 30-site library (2.15 × 109 variants) revealed reduced population-wide fitness, numerous individual variants were found to have activity and stability better than the wild type despite bearing 13 or more deimmunizing mutations per enzyme. The immunogenic potential of one highly active and stable 14-mutation variant was assessed further using ex vivo cellular immunoassays, and the variant was found to silence T-cell activation in seven of the eight blood donors who responded strongly to wild-type P99βL. In summary, our multiobjective library-design process readily identified large and mutually compatible sets of epitope-deleting mutations and produced highly active but aggressively deimmunized constructs in only one round of library screening.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Advances in protein structure prediction and design
Brian Kuhlman,Philip Bradley +1 more
TL;DR: Improvements in computational algorithms and technological advances have dramatically increased the accuracy and speed of protein structure modelling, providing novel opportunities for controlling protein function, with potential applications in biomedicine, industry and research.
Multifunctional CRISPR-Cas9 with engineered immunosilenced human T cell epitopes
Shayesteh R. Ferdosi,Radwa Ewaisha,Farzaneh Moghadam,Sri Krishna,Jin Park,Mo R. Ebrahimkhani,Mo R. Ebrahimkhani,Samira Kiani,Karen S. Anderson +8 more
TL;DR: It is demonstrated that Cas9 protein can be modified to eliminate immunodominant epitopes through targeted mutation while preserving its function and specificity and highlights the problem of pre-existing immunity against CRISPR-associated nucleases and offers a potential solution to mitigate the T cell immune response.
Immunity to CRISPR Cas9 and Cas12a therapeutics
TL;DR: Ways to assay and reduce the immunogenicity of Cas9 and Cas12a proteins are critical for ensuring patient safety and treatment efficacy, and for bringing us closer to realizing the vision of permanent genetic cures.
139
Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space
Emily K. Makowski,Patrick C. Kinnunen,Jie Huang,Lina Wu,Matthew D. Smith,Tiexin Wang,Alec A. Desai,Craig N Streu,Yulei Zhang,Jennifer M. Zupancic,John S. Schardt,Jennifer J. Linderman,Peter M. Tessier +12 more
TL;DR: In this article , the authors evaluate the use of machine learning to simplify antibody co-optimization for a clinical-stage antibody (emibetuzumab) that displays high levels of both on-antigen and off-target (non-specific) binding.
Activation of Prodrugs by NIR-Triggered Release of Exogenous Enzymes for Locoregional Chemo-photothermal Therapy.
Li Cheng,Fengrong Zhang,Shunhao Wang,Xueting Pan,Sichong Han,Shuang Liu,Junjie Ma,Hongyu Wang,Heyun Shen,Huiyu Liu,Qipeng Yuan +10 more
TL;DR: A mutually reinforcing feedback loop between PTT and chemotherapy can be initiated by the irradiation, which holds a promising future in cancer therapy.
76
References
A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach
Peng Wang,John Sidney,Courtney Dow,Courtney Dow,Bianca R. Mothé,Alessandro Sette,Bjoern Peters +6 more
TL;DR: It appears that the ability of MHC class II molecules to bind variable length peptides, which requires the correct assignment of peptide binding cores, is a critical factor limiting the performance of existing prediction tools.
891
The immunogenicity of humanized and fully human antibodies: Residual immunogenicity resides in the CDR regions
TL;DR: It is proposed that immunogenicity will always be present in some antibody molecules due to the nature of the antigen-specific combining sites and modifications to reduce immunogenic potential will be centered on the affinity-determining regions.
755
•Journal Article
Several Common HLA-DR Types Share Largely Overlapping Peptide Binding Repertoires
Scott Southwood,J Sidney,A. Kondo,del Guercio Mf,E Appella,Stephen L. Hoffman,Ralph T. Kubo,R W Chesnut,Howard M. Grey,Alessandro Sette +9 more
TL;DR: The results have implications for understanding the molecular interactions involved in peptide-DR binding, as well as the genetic and structural basis of MHC polymorphism, and potential practical implications for the development of epitope-based prophylactic and therapeutic vaccines.
712
Functional classification of class II human leukocyte antigen (HLA) molecules reveals seven different supertypes and a surprising degree of repertoire sharing across supertypes.
TL;DR: A high degree of repertoire overlap amongst all HLA class II molecules is highlighted, perhaps reflecting binding in multiple registers, and more pronounced dependence on backbone interactions rather than peptide anchor residues.
Automated design of specificity in molecular recognition.
TL;DR: A multi-state framework for engineering specificity that selects sequences maximizing the transfer free energy of a protein from a target conformation to a set of undesired competitor conformations is described.
355